Regen BioPharma Inc (RGBP)

[PressAnyKey-]

What we really like about the deals with Oncology Pharma is that Regen BioPharma is sitting on a very valuable patent portfolio. It was just a matter of time before they started monetizing it. Just doing a Google patent search yields 23 results.

These deals further validate the premise that while there has been no news from the company in almost 2 years, Regen BioPharma and its CEO David Koos have been hard at work for shareholders.

Regen BioPharma also just filed an 8-K that they intend to complete their financials. Once the company files for 2019 and 2020, the STOP sign will be removed. This will allow more brokers to list RGBP and RGBPP for their customers to trade. This is why some folks at Fidelity for instance can’t purchase shares.

https://insiderfinancial.com/otc-stock-updates-hmbl-ltnc-rgbp-sysx/181264/amp/?__twitter_impression=true